PensionDanmark Pensionsforsikringsaktieselskab Sells 12,119 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

PensionDanmark Pensionsforsikringsaktieselskab lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 35.1% during the second quarter, according to its most recent filing with the SEC. The firm owned 22,451 shares of the biopharmaceutical company’s stock after selling 12,119 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Alnylam Pharmaceuticals were worth $6,758,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. MV Capital Management Inc. bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth approximately $29,000. HM Payson & Co. bought a new stake in Alnylam Pharmaceuticals in the fourth quarter worth approximately $27,000. Golden State Wealth Management LLC lifted its stake in Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 36 shares during the period. Finally, Manchester Capital Management LLC lifted its stake in Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 72 shares during the period. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Trading Up 1.4%

NASDAQ ALNY opened at $219.20 on Friday. The company has a quick ratio of 3.06, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a 52 week low of $197.81 and a 52 week high of $495.55. The business has a 50 day moving average price of $280.12 and a 200-day moving average price of $306.27. The company has a market cap of $29.33 billion, a price-to-earnings ratio of 40.74 and a beta of 0.30.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $455 price target. Although the firm lowered its 2026, 2028, 2029 and 2030 EPS forecasts, it raised its FY2027 estimate to $9.50 from $8.13, signaling expectations for continued longer-term earnings growth. HC Wainwright estimates for Alnylam Pharmaceuticals
• Neutral Sentiment: Several HC Wainwright revisions reduced projected EPS, including Q3 2026 to $1.65 from $1.79, Q4 2026 to $1.97 from $2.23, and FY2026 to $6.30 from $6.51. The firm’s estimates remain broadly positive beyond 2026, reaching $19.42 per share by FY2030, but the near-term reductions could limit enthusiasm. Alnylam Pharmaceuticals earnings estimates
• Neutral Sentiment: An AAII comparison examines whether Alnylam or Halozyme Therapeutics is the more attractive investment. The article may influence investor preferences, but it does not identify a new company-specific operating catalyst. Which Is a Better Investment, Alnylam Pharmaceuticals, Inc. or Halozyme Therapeutics, Inc. Stock?
• Neutral Sentiment: Options-market implied volatility for ALNY has surged, pointing to increased expectations for price movement and trading risk rather than a clear bullish or bearish fundamental signal. Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options
• Negative Sentiment: Truist Financial lowered its price target on Alnylam to $315, a more cautious valuation view that could weigh on the stock and reflects concern about the company’s risk-reward profile. Truist Financial Lowers Alnylam Pharmaceuticals Price Target

Analyst Ratings Changes

Several analysts have recently commented on ALNY shares. Oppenheimer reduced their price objective on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Barclays cut their target price on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a research note on Monday, August 3rd. Sanford C. Bernstein upgraded shares of Alnylam Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, July 29th. Citigroup decreased their price target on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. Finally, Wells Fargo & Company dropped their price objective on shares of Alnylam Pharmaceuticals from $377.00 to $316.00 and set an “equal weight” rating on the stock in a report on Friday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $396.72.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares in the company, valued at approximately $473,302.76. The trade was a 70.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.